We specialize in the interface between infectious diseases and microbiota health

 

Here at The Garey Lab, it is our goal to perform collaborative, multi-faceted translational research and training surrounding the microbiome, Clostridioides difficile, and other hospital-acquired or antimicrobial resistant pathogens.

 
 
KG2.png
 

Director’s Welcome

Dr. Kevin W. Garey, PharmD, MS, FIDSA, FASHP

The Garey Lab was founded on our belief that disruptions in the healthy balance between our bodies and the microorganisms that live in and on them cause many infectious and chronic diseases.  Our translational microbiology and microbiome lab focuses on three main areas to help address this process: 1) judicious use of antibiotics and diagnostic stewardship to reduce overall antibiotic exposures, 2) new drug development to help us combat infections with multidrug-resistant organisms, and 3) assessment of microbiome changes associated with antibiotic use and acute and chronic diseases.  

On this website, you will find a variety of resources. You will find our current and prior lab group- it is a wonderful showcase of our talent and successful graduates.  We have also highlighted several techniques our lab uses as well as information on the services we offer potential collaborators. Finally, we have our publications and recent presentations available in order to provide our scholarly work to the scientific community and other interested persons.

Please send us a note if you have any questions or interest in collaborating. Thank you for visiting our website!

 

A history of collaboration & ground-breaking research

We have a history of success in conducting microbiology, molecular biology, and phase I-IV clinical trials. With active collaborations with academic, governmental, and industry partners, we offer high quality resources and expertise.

ongoing trials & volunteer opportunities

Our work depends on volunteers in the community and surrounding hospitals who choose to help advance our science. We are actively recruiting interested persons for a variety of ongoing trials in healthy and sick people.

 

THE GAREY LAB IN THE NEWS

Dr. Garey honored with 2023 Innovator Award for Development of Cdiff32 Quality-of-Life Instrument. (November 2023) The Peggy Lillis Foundation presented him with the award during their annual Changing the Odds Gala in Brooklyn, New York. Read more from UHCOP

Drs. Gonzales-Luna / Garey awarded grant from American College of Clinical Pharmacy. (January 2022) The ACCP Foundation Futures Grant will fund continuing research on the role of vancomycin resistance in C. difficile. Read more from UHCOP

C. Difficile Is Everywhere – Even On The Bottom Of Footwear. (October 2021) Research led by Dr. Jinhee Jo and conducted by the Garey Lab was highlighted by the IDSA as a part of the 2021 IDWeek meeting. Read more from IDSA

Garey Achieves Fellow Status in American College of Clinical Pharmacy. (September 2021) Dr. Garey was elected as a 2021 Fellow of ACCP and will be recognized during the virtual 2021 ACCP Annual Meeting in October. Read more from UHCOP

New Clinical Practice Guidelines for the Management of C. difficile Infection in Adults Published. (June 2021) Two Garey Lab faculty members, Drs. Kevin Garey and Anne Gonzales-Luna, were included as a part of the expert panel of authors. Read related press releases from Oxford

Garey Named Fellow of Prestigious Infectious Diseases Society of America. (December 2020) Dr. Garey was one of 182 distinguished physicians and scientists from the United States and around the world recognized with the prestigious designation of FIDSA. Read more from UHCOP

Ability to Predict C. difficile Mortality Nearly Doubled with New Guidelines. (December 2020) A recent publication by students, fellows, and faculty in the Garey lab validates a measure of kidney injury previously recommended based on expert opinion. Read more from UH

 

The Garey Lab on Twitter